1. Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir. Issue 2 (28th November 2016) Authors: Xu, J.‐H.; Song, L.‐W.; Li, N.; Wang, S.; Zeng, Z.; Si, C.‐W.; Li, J.; Mao, Q.; Zhang, D.‐Z.; Tang, H.; Sheng, J.‐F.; Chen, X.‐Y.; Ning, Q.; Shi, G.‐F.; Xie, Q.; Yuan, Q.; Yu, Y.‐Y.; Xia, N.‐S. Journal: Journal of viral hepatitis Issue: Volume 24:Issue 2(2017) Page Start: 148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: Results at week 144. Issue 10 (11th August 2017) Authors: Xu, J.‐H.; Wang, S.; Xu, Z.‐N.; Yu, Y.‐Y.; Si, C.‐W.; Zeng, Z.; Li, J.; Mao, Q.; Zhang, D.‐Z.; Tang, H.; Sheng, J.‐F.; Chen, X.‐Y.; Ning, Q.; Shi, G.‐F.; Xie, Q.; Zhang, X.‐Q.; Dai, J. Journal: Journal of viral hepatitis Issue: Volume 24:Issue 10(2017) Page Start: 877 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗